Xenetic Biosciences Inc Stock Price, News & Analysis

Xenetic Biosciences, Inc. (NASDAQ: XBIO) will participate in a Virtual Investor Innovation in Oncology Event on June 9, 2022, at 11:00 AM ET. The event features a roundtable with CEO Jeffrey Eisenberg, Chief Scientific Officer Curtis Lockshin, and oncology expert Allan Tsung, MD. They will discuss Xenetic's DNase-based oncology platform, focusing on how it targets Neutrophil Extracellular Traps (NETs) in cancer treatment. A live video webcast will be available on the Company's website, and questions from the audience will be addressed during the session.

Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 PM ET. CEO Jeffrey F. Eisenberg will deliver the presentation in Miami, FL, and virtually. The management team will also be available for one-on-one meetings with investors. A live video webcast will be accessible on the Company's website and archived for 90 days. Xenetic is advancing therapies targeting Neutrophil Extracellular Traps and developing CAR T platform technology.

Xenetic Biosciences (NASDAQ: XBIO) reported its first quarter 2022 financial results, highlighting a net loss of approximately $1.6 million and cash reserves of $16.2 million. The company has completed an exclusive licensing agreement with CLS Therapeutics for a DNase-based oncology platform aimed at enhancing cancer treatment outcomes. The focus is on advancing this platform for Phase 1 clinical development targeting locally advanced or metastatic solid tumors, with an IND filing anticipated by the end of 2023.

Xenetic Biosciences (NASDAQ: XBIO) has announced a transaction with CLS Therapeutics to develop a DNase-based oncology platform, which aims to enhance the efficacy of existing therapies for solid tumors. This includes an exclusive license for DNases in cancer treatment, entailing an upfront payment of $500,000, issuance of shares, and future milestone payments potentially reaching $13 million. The company plans to conduct a Phase 1 clinical study targeting locally advanced or metastatic cancers. The platform seeks to address issues related to Neutrophil Extracellular Traps (NETs), which may hinder cancer treatment outcomes.

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of $5.6 million for the year ended December 31, 2021, with research and development expenses rising to $3.2 million. The company ended the year with cash reserves of approximately $18.2 million and working capital of about $17.3 million, up from $11.4 million in 2020. Their XCART platform is advancing toward IND-enabling studies, while royalty payments from the PolyXen technology reached $1.2 million, a 166% increase from the previous year. The XCART program targets a potential global market of over $7 billion annually.

Xenetic Biosciences (NASDAQ: XBIO) is advancing its XCART platform towards IND-enabling studies, backed by a strengthened cash position from a recent $12.5 million private placement. The company reported a net loss of $1.4 million for Q3 2021, with R&D expenses rising by 36.1% to $0.8 million. Additionally, royalty streams have grown through its license agreement with PolyXen^®, bringing in approximately $0.3 million in royalties. With working capital at $19.5 million, Xenetic is positioned to pursue its innovative cancer therapies effectively.

Xenetic Biosciences (NASDAQ: XBIO) announced a Notice of Allowance from the USPTO for its patent application covering its XCART personalized CAR T therapy. This platform targets tumor-specific neoantigens and aims to improve cancer treatment effectiveness. CEO Jeffrey Eisenberg highlighted this as a significant milestone for the XCART program, which is currently in pre-clinical development for Non-Hodgkin lymphoma. The resulting U.S. patent is expected to expire in 2038, enhancing the company's intellectual property portfolio.

Xenetic Biosciences (NASDAQ: XBIO) has announced that CEO Jeffrey F. Eisenberg will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the Company's personalized CAR T platform technology, XCART™, designed to target patient-specific tumor neoantigens. A video webcast of the presentation will be available on-demand starting September 13 at 7:00 AM ET, with a replay accessible for 90 days. The Company is also leveraging its PolyXen® platform for drug delivery improvements.

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of approximately $1.1 million for Q2 2021, with R&D expenses increasing 70.4% to $0.5 million due to advancements in its XCART platform. The company strengthened its position through a $12.5 million private placement and saw royalty growth from its PolyXen technology, totaling about $0.3 million in royalties generated from Takeda's sublicensee. The company is progressing towards IND-enabling studies in the U.S., aiming to address a significant market opportunity in oncology.